The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Functional evaluation of the P681H mutation on the proteolytic activation of the SARS-CoV-2 variant B.1.1.7 (Alpha) spike
Open accessPublished version of a preprint
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the agent causing the COVID-19 pandemic. SARS-CoV-2 B.1.1.7 (Alpha), a WHO variant of concern first identified in the United Kingdom in late 2020, contains several mutations including P681H in the spike S1/S2 cleavage site, which is predicted to increase cleavage by furin, potentially impacting the viral cell entry. Here, we studied the role of the P681H mutation in B.1.1.7 cell entry. We performed assays using fluorogenic peptides mimicking the Wuhan-Hu-1 and B.1.1.7 S1/S2 sequence and observed no significant difference in furin cleavage. Functional assays using pseudoparticles harboring SARS-CoV-2 spikes and cell-to-cell fusion assays demonstrated no differences between Wuhan-Hu-1, B.1.1.7, or a P681H point mutant. Likewise, we observed no differences in viral growth between USA-WA1/2020 and a B.1.1.7 isolate in cell culture. Our findings suggest that, although the B.1.1.7 P681H mutation may slightly increase S1/S2 cleavage, this does not significantly impact viral entry or cell-cell spread.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2021) · Science · doi:10.1126/science.abg3055 · Cited by 2,581
Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
Davies, N. G., Abbott, S., Barnard, R. C., Jarvis, C. I., Kucharski, A. J., Munday, J. D., Pearson, C. A. B., Russell, T. W., Tully, D. C., Washburne, A. D., et al. (2020) · doi:10.1101/2020.12.24.20248822 · Cited by 2,557
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England
The COVID-19 Genomics UK (COG-UK) consortium, Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., et al. (2021) · Nature · doi:10.1038/s41586-021-03470-x · Cited by 1,611
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.013 · Cited by 1,353
Challen, R., Brooks-Pollock, E., Read, J. M., Dyson, L., Tsaneva-Atanasova, K., & Danon, L. (2021) · BMJ · doi:10.1136/bmj.n579 · Cited by 776 · cited 1×
“Current consensus indicates that this VOC has a transmission advantage in the community (Davies et al., 2021; Volz et al., 2021), possibly accompanied by increased disease severity (Challen et al., 2021), but it does not appear to evade immune surveillance by natural immunity or vaccination.”
Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence
Sabino, E. C., Buss, L. F., Carvalho, M. P. S., Prete, C. A., Crispim, M. A. E., Fraiji, N. A., Pereira, R. H. M., Parag, K. V., da Silva Peixoto, P., Kraemer, M. U. G., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00183-5 · Cited by 758
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01318-5 · Cited by 697
Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis
Johnson, B. A., Xie, X., Bailey, A. L., Kalveram, B., Lokugamage, K. G., Muruato, A., Zou, J., Zhang, X., Juelich, T., Smith, J. K., et al. (2021) · Nature · doi:10.1038/s41586-021-03237-4 · Cited by 694
Research works printed but not linked: 30
- Belouzard, 2009, Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites, Proc. Natl. Acad. Sci., 106, 5871, 10.1073/pnas.0809524106 · DOI · Paper page
- Brown, 2021, Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is not accounted for by a replicative advantage in primary airway cells or antibody escape, bioRxiv
- Chan, 2020, A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster, Lancet, 395, 514, 10.1016/S0140-6736(20)30154-9 · DOI · Paper page
- Coutinho, 2021, Model-based estimation of transmissibility and reinfection of SARS-CoV-2 P.1 variant, Commun. Med., 1, 48, 10.1038/s43856-021-00048-6 · DOI
- de Oliveira, 2021, A novel variant of interest of SARS-CoV-2 with multiple spike mutations detected through travel surveillance in Africa, medRxiv
- Di Caro, 2021, Severe acute respiratory syndrome coronavirus 2 escape mutants and protective immunity from natural infections or immunizations, Clin. Microbiol. Infect., 27, 823, 10.1016/j.cmi.2021.03.011 · DOI
- Dicken, 2021, Characterisation of B.1.1.7 and Pangolin coronavirus spike provides insights on the evolutionary trajectory of SARS-CoV-2, bioRxiv
- Duckert, 2004, Prediction of proprotein convertase cleavage sites, Protein Eng. Des. Select., 17, 107, 10.1093/protein/gzh013 · DOI · Paper page
- Dudas, 2021, Emergence and spread of SARS-CoV-2 lineage B.1.620 with variant of concern-like mutations and deletions, Nat. Commun., 12, 5769, 10.1038/s41467-021-26055-8 · DOI
- Follis, 2006, Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell–cell fusion but does not affect virion entry, Virology, 350, 358, 10.1016/j.virol.2006.02.003 · DOI · Paper page
- Goodman, 2021, Public health surveillance of infectious diseases: beyond point mutations, Lancet Microbe., 2, e53, 10.1016/S2666-5247(21)00003-3 · doi:10.1016/s2666-5247(21)00003-3
- Jaimes, 2020, Phylogenetic analysis and structural modeling of SARS-CoV-2 spike protein reveals an evolutionary distinct and proteolytically sensitive activation loop, J. Mol. Biol., 432, 3309, 10.1016/j.jmb.2020.04.009 · DOI · Paper page
- Jaimes, 2019, A fluorogenic peptide cleavage assay to screen for proteolytic activity: applications for coronavirus spike protein activation, J. Vis. Exp., 143, 1
- Jaimes, 2020, Proteolytic cleavage of the SARS-CoV-2 spike protein and the role of the novel S1/S2 site, iScience, 23, 101212, 10.1016/j.isci.2020.101212 · DOI · Paper page
- Jin, 2020, Virus strain from a mild COVID-19 patient in Hangzhou represents a new trend in SARS-CoV-2 evolution potentially related to Furin cleavage site, Emerging microbes & infections, 9, 1474, 10.1080/22221751.2020.1781551 · DOI
- Kissler, 2021, Densely sampled viral trajectories for SARS-CoV-2 variants alpha (B.1.1.7) and epsilon (B.1.429), medRxiv
- Lasek-Nesselquist, 2021, A tale of three SARS-CoV-2 variants with independently acquired P681H mutations in New York State, medRxiv
- Liu, 2021, Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant, bioRxiv
- Lubinski, 2021, Spike protein cleavage-activation mediated by the SARS-CoV-2 P681R mutation: a case-study from its first appearance in variant of interest (VOI) A.23.1 identified in Uganda, bioRxiv
- Maison, 2021, Genetic characteristics and phylogeny of 969-bp S gene sequence of SARS-CoV-2 from Hawaii reveals the worldwide emerging P681H mutation, bioRxiv
- Millet, 2019, Production of pseudotyped particles to study highly pathogenic coronaviruses in a biosafety level 2 setting, J. Vis. Exp., 145, 1
- Peacock, 2020, The furin cleavage site of SARS-CoV-2 spike protein is a key determinant for transmission due to enhanced replication in airway cells, bioRxiv
- Peacock, 2021, The SARS-CoV-2 variants associated with infections in India, B.1.617, show enhanced spike cleavage by furin, bioRxiv
- Saito, 2021, SARS-CoV-2 spike P681R mutation, a hallmark of the Delta variant, enhances viral fusogenicity and pathogenicity, bioRxiv
- Seidah, 2012, The biology and therapeutic targeting of the proprotein convertases, Nat. Rev. Drug Discov., 11, 367, 10.1038/nrd3699 · DOI · Paper page
- Tang, 2021, Proteolytic activation of SARS-CoV-2 spike at the S1/S2 boundary: potential role of proteases beyond furin, ACS Infect. Dis., 7, 264, 10.1021/acsinfecdis.0c00701 · DOI
- Tegally, 2021, Sixteen novel lineages of SARS-CoV-2 in South Africa, Nat. Med., 27, 440, 10.1038/s41591-021-01255-3 · DOI · Paper page
- Tian, 2012, Computational prediction of furin cleavage sites by a hybrid method and understanding mechanism underlying diseases, Sci. Rep., 2, 261, 10.1038/srep00261 · DOI
- Zhang, 2021, Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant, bioRxiv, eabl9463
- Zhou, 2021, SARS-CoV-2 spike D614G change enhances replication and transmission, Nature, 592, 122, 10.1038/s41586-021-03361-1 · DOI · Paper page
Cited by
SARS-CoV-2 variant biology: immune escape, transmission and fitness
Carabelli, A. M., Peacock, T. P., Thorne, L. G., Harvey, W. T., Hughes, J., COVID-19 Genomics UK Consortium, de Silva, T. I., Peacock, S. J., Barclay, W. S., de Silva, T. I., et al. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00841-7 · Cited by 1,291
SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo
Hui, K. P. Y., Ho, J. C. W., Cheung, M.-C., Ng, K.-C., Ching, R. H. H., Lai, K.-L., Kam, T. T., Gu, H., Sit, K.-Y., Hsin, M. K. Y., et al. (2022) · Nature · doi:10.1038/s41586-022-04479-6 · Cited by 836
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7
Meng, B., Kemp, S. A., Papa, G., Datir, R., Ferreira, I. A. T. M., Marelli, S., Harvey, W. T., Lytras, S., Mohamed, A., Gallo, G., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109292 · Cited by 405
The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages
Martin, D. P., Weaver, S., Tegally, H., San, J. E., Shank, S. D., Wilkinson, E., Lucaci, A. G., Giandhari, J., Naidoo, S., Pillay, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.003 · Cited by 291
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2
Uraki, R., Kiso, M., Iida, S., Imai, M., Takashita, E., Kuroda, M., Halfmann, P. J., Loeber, S., Maemura, T., Yamayoshi, S., et al. (2022) · Nature · doi:10.1038/s41586-022-04856-1 · Cited by 273
Metadata
- Authors
- Lubinski, B., Fernandes, M. H. V., Frazier, L., Tang, T., Daniel, S., Diel, D. G., Jaimes, J. A., & Whittaker, G. R.
- Venue
- iScience
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 25
- Issue
- 1
- Pages
- 103589
- ISSN
- 2589-0042 (ISSN-L)
- OpenAlex
- W4200373171
- Cited by
- 182
- References
- 15
- FWCI
- 12.29
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- National Science Foundation (DGE-1650441)
- National Institutes of Health (R01AI35270)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Functional evaluation of the P681H mutation on the proteolytic activation of the SARS-CoV-2 variant B.1.1.7 (Alpha) spike. https://app.cochat.ai/papers/10.1016/j.isci.2021.103589
- The paper
- Lubinski, B., Fernandes, M. H. V., Frazier, L., Tang, T., Daniel, S., Diel, D. G., Jaimes, J. A., & Whittaker, G. R. (2022). Functional evaluation of the P681H mutation on the proteolytic activation of the SARS-CoV-2 variant B.1.1.7 (Alpha) spike. iScience. https://doi.org/10.1016/j.isci.2021.103589
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.